Huabo Biopharm (shanghai) Co., Ltd.

Mingqing Cai

Xiangyang Zhu

Ling Yu

Haijia Yu

Lei Zhang

Shi Chen

Huifeng Jia

Fengxue Zhang

Provided is an anti-PD-L1 monoclonal antibody. The antibody can be used to prepare a drug for preventing or treating a disease related to PD-L1.

Binder against programmed death-ligand and application thereof

The present invention provides an anti-PD-L1/VEGF bispecific antibody and a use thereof. Specifically, the present invention provides a bifunctional antibody, comprising: (a) anti-PD-L1 antibody or element; and (b) an anti-VEGF antibody or element linked to the anti-PD-L1 antibody or element. The bifunctional antibody of the present invention can simultaneously bind to VEGF and PD-L1, thereby exerting a therapeutic effect on VEGF and PD-L1-positive tumor cells (especially malignant tumor cells).

Anti-PD-L1/VEGF bifunctional antibody and use thereof

The present invention provides an antibody targeted to interleukin 17A (IL-17A), preparation method and the use thereof. In particular, the invention provides a novel anti-IL-17A monoclonal antibody. The antibody of the present invention is capable of binding IL-17A antigen with high specificity, has high affinity and low immunogenicity, and is used for preparing a medicament for preventing or treating an IL-17A-related disease such as various inflammatory or autoimmune diseases.

Antibody targeting interleukin 17A and preparation method and application thereof

Growing community of inventors

Shanghai, China

Mingqing Cai